SHSeth A. Hoffman

Seth A. Hoffman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seth A. Hoffman has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Germicidal ultraviolet to reduce transmission of respiratory infections indoors: a systematic review

    by Grant P. Higerd-Rusli, Erin C. Stone, Seth A. Hoffman, Ernest R. Blatchley, David T. Kuhar, Stephen P. Luby, Stephen B. Martin, Richard A. Martinello, C. Cameron Miller, Katherine Ratliff, et al.

    Background: Respiratory infections that transmit through air contribute substantially to global morbidity and mortality. Although preclinical data on germicidal ultraviolet (GUV) for air treatment are promising, its real-world effectiveness remains incompletely understood. Purpose: Review effectiveness and safety of GUV for preventing respiratory infection transmission. Data sources: Medline, Embase, Global Health, Cochrane Library, CINAHL, Engineering Village, Epistemonikos, Scopus, and Environmental Science Collection from inception through December 2025. Study selection: Studies of GUV with a comparator, measuring human outcomes including respiratory infections, absenteeism, or adverse events. Data extraction: At least two investigators extracted data. Data synthesis: We identified 57 reports describing 40 studies published between 1940 and 2025: 30 non-randomized controlled trials, 4 randomized controlled trials (RCTs), 4 case series, 1 cohort study, and 1 cross-sectional study. Non-randomized studies indicated GUV reduces infections with high transmissibility through air (measles and chickenpox), although results were mixed for undifferentiated respiratory illnesses and absenteeism. Two RCTs were inconclusive or showed only modest effects. Safety monitoring in 16 studies identified no increased eye or skin irritation from properly installed GUV. All studies had at least one threat to validity; 89% were non-randomized, and 83% lacked statistical power calculations. Limitations: Heterogeneous study designs, interventions, and outcomes precluded meta-analysis. Conclusions: Several older clinical studies indicated that GUV reduces infections with high transmissibility through air, but its broader effectiveness against respiratory infection remains uncertain. Inconclusive results may reflect methodological and epidemiological limitations rather than true ineffectiveness. Adequately powered RCTs with robust clinical endpoints are needed. Registration: https://osf.io/fg6qx

  • Open Access

    Validation of sample pooling for high-throughput RT-qPCR subtyping of avian influenza A(H5)

    by Grant P. Higerd-Rusli, Seth A. Hoffman, Abraar Karan, ChunHong Huang, Malaya K. Sahoo, Ingrid E. A. Morante, Matthew M. Hernandez, Benjamin A. Pinsky

    Highly pathogenic avian influenza A(H5N1) is a global health threat due to its high historical virulence and increasing mammalian host range, as demonstrated by the 2024–2025 outbreak among U.S. dairy cattle, with 71 confirmed human infections. While human-to-human transmission has not yet been documented, limited pre-existing human immunity, and uncertainty about evolutionary barriers to human infection make H5N1 a potential pandemic threat. Expanding testing capacity for H5N1 beyond its currently limited scope would be critical for response to potential outbreaks. Thus, we developed and validated a dual-target reverse transcription PCR assay for H5 subtyping of pooled influenza A-positive samples. The assay targets two regions of the hemagglutinin (HA) gene of influenza A(H5). Using contrived samples containing inactivated bovine H5N1 virus, we determined the assay’s 95% lower limit of detection for individual samples (58 copies/mL; 95% confidence interval [CI]: 50 to 66 copies/mL) and eight-sample pools (2,465 copies/mL; 95% CI: 1,969 to 3,756 copies/mL). The assay demonstrated 100% positive percent agreement, detecting H5 in all contrived H5-positive pools (32/32 pools; 95% CI: 89.1% to 100.0%) where the contrived positive samples ranged from 500,000 to 3,906 copies/mL. We observed 100% negative percent agreement in H5-negative, influenza A-positive pools (32/32; 95% CI: 89.1% to 100.0%). Though sample pooling reduced analytical sensitivity, contrived samples with H5 virus present at levels typically found in human respiratory infections were detected in eight-sample pools. This approach has the potential to increase testing capacity for influenza A (H5) while maintaining adequate sensitivity, enhancing preparedness for potential outbreaks. IMPORTANCE: Avian influenza A(H5N1) poses a potential pandemic threat. H5N1 testing capacity is currently limited. We validated an influenza A (H5) subtyping RT-qPCR for testing pooled samples to increase capacity. The assay displays adequate analytical sensitivity to detect clinical respiratory infections based on prior human cases. This proactive assay validation enhances outbreak preparedness.

  • The Role and Safety of Aluminum Adjuvants in Childhood Vaccines

    by Edward Nirenberg, Yvonne A. Maldonado, Seth A. Hoffman

    Aluminum salts have been used as adjuvants in vaccines for nearly a century, enhancing the immune response to purified antigens and ensuring durable protection against serious infectious diseases. Despite their longstanding record of safety and effectiveness, aluminum adjuvants have become a focus of public concern, with claims linking them to developmental, neurologic, allergic, and autoimmune diseases. This review summarizes the immunologic rationale for aluminum adjuvants and evaluates the evidence for proposed safety risks. Aluminum salts have consistently been demonstrated over nearly a century of use to enhance the immune responses elicited by vaccines while also being well tolerated by nearly all who take them. Pharmacokinetic studies show that aluminum released from intramuscular vaccines is slowly absorbed and efficiently cleared by the kidneys, contributing minimally to systemic levels. Large-scale clinical and epidemiologic studies consistently demonstrate no association between aluminum-adjuvanted vaccines and autism spectrum disorder, neurotoxicity, allergic disease, or autoimmune disease. Clinically, vaccines adjuvanted solely with aluminum salts generally do not result in systemic reactogenicity, although local reactions are common. Collectively, the evidence strongly supports the safety of aluminum adjuvants and their necessity in certain vaccines. Clinicians can reassure caregivers that aluminum-containing vaccines provide clear benefits, with risks largely limited to transient local reactions and no systemic toxicity signal in large clinical and epidemiologic studies.


  • Open Access

    One confirmed and one potential human case of influenza A(H5N1) detected through an expanded subtyping protocol

    by Grant P. Higerd-Rusli, Abraar Karan, Seth A. Hoffman, Ingrid E. A. Morante, ChunHong Huang, Malaya K. Sahoo, Matthew M. Hernandez, Benjamin A. Pinsky

    Current U.S. surveillance for highly pathogenic avian influenza A(H5N1) in humans prioritizes individuals with known animal exposures, potentially missing community-acquired infections. To address this gap, we implemented universal H5 subtyping of all influenza A-positive respiratory samples collected within our hospital system, regardless of patient exposure history. Between August 2024 and April 2025, we subtyped 4,488 influenza A-positive samples and identified two cases positive for H5 RNA in Alameda County, California, USA. The first case was a 14-month-old girl with mild respiratory symptoms and no H5N1 exposure risks; sequencing of the sample revealed an H5 gene closely related to clade 2.3.4.4b, genotype B3.13 viruses circulating in U.S. dairies. The second case was a 79-year-old male, also with no known exposures, whose sample reproducibly tested positive with a high cycle threshold value but could not be confirmed by public health laboratories. Both patients had evidence of co-infection with other common respiratory viruses. These findings, while requiring cautious interpretation due to low virus levels and the presence of potential confounding factors, highlight limitations in exposure-based testing and demonstrate the potential for cryptic H5N1 circulation. This report underscores that broader, geographically targeted surveillance may be a critical tool for early detection of potential community transmission of pandemic-capable pathogens.


  • Open Access

    Factors Influencing Vaccine Receipt During a 2018 Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India

    by Priyanka Borhade, Christopher LeBoa, Niniya Jayaprasad, Kashmira Date, Pradeep Haldar, Pauline Harvey, Rahul Shimpi, Qian An, Chenhua Zhang, Lily Horng, et al.

    : In 2018, the Navi Mumbai Municipal Corporation implemented phase 1 of a public sector typhoid conjugate vaccine campaign in Navi Mumbai, India, targeting all children aged 9 months to 14 years within its administrative boundaries. To assess associations with receipt of vaccine in phase 1, we used generalized estimating equations to calculate estimates of vaccination by child-, household-, and community-level demographics (child education and age; household head education, income, and occupation; community informal settlement percent). Campaign vaccine receipt was most associated with children enrolled in school (odds ratio [OR] = 3.84, 95% CI: 2.18–6.77), the lowest household income tertile when divided into three equal parts (OR = 1.64, 95% CI: 1.43–1.84), and lower community-level socioeconomic status (OR = 1.06, 95% CI: 1.04–1.08 per 10% informal settlement proportion). The campaign was successful in reaching the most underserved populations of its target communities.

  • Open Access

    Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign

    by Kashmira Date, Christopher LeBoa, Seth A. Hoffman, Pradeep Haldar, Pauline Harvey, Qian An, Chenhua Zhang, Vijay N. Yewale, Savita Daruwalla, Dhanya Dharmapalan, et al.

    Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05–0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0–95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.


  • Open Access

    Emerging and re-emerging pediatric viral diseases: a continuing global challenge

    by Seth A. Hoffman, Yvonne A. Maldonado

    The twenty-first century has been marked by a surge in viral epidemics and pandemics, highlighting the global health challenge posed by emerging and re-emerging pediatric viral diseases. This review article explores the complex dynamics contributing to this challenge, including climate change, globalization, socio-economic interconnectedness, geopolitical tensions, vaccine hesitancy, misinformation, and disparities in access to healthcare resources. Understanding the interactions between the environment, socioeconomics, and health is crucial for effectively addressing current and future outbreaks. This scoping review focuses on emerging and re-emerging viral infectious diseases, with an emphasis on pediatric vulnerability. It highlights the urgent need for prevention, preparedness, and response efforts, particularly in resource-limited communities disproportionately affected by climate change and spillover events. Adopting a One Health/Planetary Health approach, which integrates human, animal, and ecosystem health, can enhance equity and resilience in global communities. Impact: We provide a scoping review of emerging and re-emerging viral threats to global pediatric populations This review provides an update on current pediatric viral threats in the context of the COVID-19 pandemic This review aims to sensitize clinicians, epidemiologists, public health practitioners, and policy stakeholders/decision-makers to the role these viral diseases have in persistent pediatric morbidity and mortality


  • Open Access

    Assessment of environmental sources of arsenic, lead, and cadmium exposure among pregnant women in rural, Bangladesh

    by Musa Baker, Allison R Sherris, Ferdous Anowar, Hafsa Hossain Atia, Jesmin Sultana, Mohammad Sabbir Ahmed, Nairita Ahsan Faruqui, Christlee Doris Elmera, Seth Hoffman, Ahmed Moutwakil, et al.

  • Open Access

    Retrospective Review of Blood Culture-Confirmed Cases of Enteric Fever in Navi Mumbai, India: 2014–2018

    by Niniya Jayaprasad, Priyanka Borhade, Christopher LeBoa, Kashmira Date, Shrikrishna Joshi, Rahul Shimpi, Jason R. Andrews, Stephen P. Luby, Seth A. Hoffman

    India has one of the highest estimated burdens of enteric fever globally. Prior to the implementation of Typbar-TCV typhoid conjugate vaccine (TCV) in a public sector pediatric immunization campaign in Navi Mumbai, India, we conducted a retrospective review of blood culture-confirmed cases of typhoid and paratyphoid fevers to estimate the local burden of disease. This review included all blood cultures processed at a central microbiology laboratory, serving multiple hospitals, in Navi Mumbai (January 2014–May 2018) that tested positive for either Salmonella Typhi or Salmonella Paratyphi A. Of 40,670 blood cultures analyzed, 1,309 (3.2%) were positive for S. Typhi (1,201 [92%]) or S. Paratyphi A (108 [8%]). Culture positivity was highest in the last months of the dry season (April–June). Our findings indicate a substantial burden of enteric fever in Navi Mumbai and support the importance of TCV immunization campaigns and improved water, sanitation, and hygiene.


  • Open Access

    Retrospective Review of Blood Culture-Confirmed Cases of Enteric Fever in Navi Mumbai, India: 2014–2018

    by Niniya Jayaprasad, Priyanka Borhade, Christopher LeBoa, Kashmira Date, Shrikrishna Joshi, Rahul Shimpi, Jason R. Andrews, Pankaj Bhatnagar, Stephen P. Luby, Seth A. Hoffman

    India has one of the highest estimated burdens of enteric fever globally. Prior to implementation of Typbar-TCV ® typhoid conjugate vaccine (TCV) in a public sector pediatric immunization campaign in Navi Mumbai, India, we conducted a retrospective review of blood culture-confirmed cases of typhoid and paratyphoid fevers to estimate the local burden of disease. This review included all blood cultures processed at a central microbiology laboratory, serving multiple hospitals, in Navi Mumbai (January 2014–May 2018) that tested positive for either Salmonella Typhi or Salmonella Paratyphi A. Of 40,670 blood cultures analyzed, 1,309 (3.2%) were positive for S. Typhi (1,201 [92%]) or S. Paratyphi A (108 [8%]). Culture positivity was highest in the last months of the dry season (April-June). Our findings indicate a substantial burden of enteric fever in Navi Mumbai and support the importance of TCV immunization campaigns and improved water, sanitation, and hygiene.